

Faculty of Medicine, Israel Institute of Technology, Haifa, Israel, ⁴Department of Nephrology and Hypertension, Nazareth Hospital, Nazareth Medical Missionary Society, Nazareth, Israel; and ⁵Nephrology Division, Azrieli Faculty of Medicine in Safed, Safed, Israel

Correspondence: Noa Berar Yanay, Hillel Yaffe Medical Center, Hadera, Israel 3810101. E mail: noab@hy.health.gov.il; and Zaher Armaly, Department of Nephrology and Hypertension, Nazareth Hospital, Nazareth Medical Missionary Society, Nazareth, Israel. E mail: zaherarmaly@nazhosp.com

Kidney International (2021) 99, 1496–1498; <https://doi.org/10.1016/j.kint.2021.04.006>

Copyright © 2021, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine



see commentary on page 1275

To the editor: The efficacy rates of vaccines to prevent infection with severe acute respiratory syndrome coronavirus

2 (SARS-CoV-2) have not been specifically investigated in kidney transplant recipient (KTRs). Preliminary results suggest that among KTRs who received the first injection of an mRNA-based vaccine, the antibody response is weak.^{1,2} This study reports on the immunization rates of KTRs who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine (Moderna).³

All participants had a negative history for coronavirus disease 2019 (COVID-19) and tested negative for anti-SARS-CoV-2 antibodies on the day of first injection. Serologic response was assessed on the day of the second injection and 1 month thereafter using the ARCHITECT IgG II Quant test (Abbott). Titers >50 arbitrary units (AUs)/ml were considered positive (detection range, 6.8–80,000 AUs/ml). This assay is reported to correlate with *in vitro* virus neutralization.⁴

The study sample consisted of 205 KTRs (Table 1). Only 98 patients displayed a positive serology 28 days after the second dose. The median antibody titer was 803.2 AUs/ml (interquartile range, 142.6–4609.6 AUs/ml). Compared with patients who did not respond after the first injection, patients with a positive serology after the first dose (n = 24 [11.7%]) displayed a higher antibody titer after the second injection (104 vs. 9415 AUs/ml, respectively; $P = 7.3^{-11}$). Antibody titers measured 1 month after the first and second

Table 1 | Characteristics of kidney transplant recipients stratified according to the serologic response after 2 doses of the mRNA-1273 SARS-CoV-2 vaccine

Characteristics	Entire cohort (n = 204) ^a	SARS CoV 2 seronegative patients (n = 106)	SARS CoV 2 seropositive patients (n = 98)	P	Missing data
Age, yr	57.7 (49.4 67.5)	58 (51 67.7)	57.3 (46.9 66.2)	0.45	0
Male sex	130 (63.8)	66 (62.3)	64 (65.3)	0.66	0
BMI, kg/m ²	25.6 (22.4 28.5)	25.4 (22.3 27.6)	25.9 (22.6 29.9)	0.3	2
Time from kidney transplantation, yr	6.2 (3 12.8)	5.4 (2.4 12)	7.1 (3.8 14.7)	0.04	1
First transplantation	170 (83.3)	80 (75.5)	90 (91.8)	0.002	0
Deceased donor	163 (79.9)	84 (79.3)	79 (80.6)	0.86	0
ABO group				0.1	2
O	84 (41.6)	38 (36.5)	46 (46.9)		
A	86 (42.6)	48 (46.2)	38 (38.8)		
B	11 (10.9)	15 (14.4)	7 (7.1)		
AB	10 (5)	3 (2.9)	7 (7.1)		
Induction treatment				0.5	9
Anti thymocyte globulin	118 (60.5)	63 (61.8)	55 (59.1)		
Anti CD25	70 (35.9)	37 (36.3)	33 (35.5)		
No induction	7 (3.6)	2 (2)	5 (5.4)		
CNI				0.13	0
Tacrolimus	115 (56.4)	67 (63.2)	48 (49)		
Cyclosporine	73 (35.8)	32 (30.2)	41 (41.8)		
No CNI	16 (7.8)	7 (6.6)	9 (9.2)		
MMF/MPA	161 (78.9)	91 (85.9)	70 (71.4)	0.02	0
Azathioprine	6 (2.9)	0	6 (6.12)	0.01	0
mTOR inhibitors	27 (13.2)	9 (8.5)	18 (18.4)	0.04	0
Steroids	122 (59.8)	69 (65.1)	53 (54.1)	0.12	0
Tacrolimus + MMF/MPA	98 (48)	60 (56.6)	38 (38.8)	0.001	0
Tacrolimus + MMF/MPA + steroids	64 (31.3)	46 (43.4)	18 (18.4)	0.0001	0
Belatacept	5 (2.5)	4 (3.8)	1 (1)	0.37	0
eGFR, ml/min per 1.73 m ²	57.1 (42.4 70.6)	54.4 (38.1 67.5)	62.5 (47.8 72.5)	0.004	1
Serum creatinine, μmol/L	120 (100 161)	137 (109 173)	110 (96 141)	0.0003	1

BMI, body mass index; CNI, calcineurin inhibitor; COVID 19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate; MMF, mycophenolate mofetil; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin; SARS CoV 2, severe acute respiratory syndrome coronavirus 2.

Continuous variables are presented as medians (interquartile ranges), whereas categorical variables are given as n (%).

^aThe patient who developed COVID 19 was excluded from the analysis.




Figure 1 | Anti-spike IgG antibody titers (arbitrary unit [AU]/ml) measured after the second injection of the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in 204 kidney transplant recipients without a history of coronavirus disease 2019 (COVID-19). Patients with titers >50 AU/ml were considered as seropositive. Bars represent median values. (a) Scattergram showing a significant positive correlation between anti-spike IgG antibody titers (AU/ml) after the first and second vaccine injections (Spearman $\rho = 0.68$; $P < 0.0001$). (b) Kidney transplant recipients being treated with antimetabolites (mycophenolate mofetil [MMF]/mycophenolic acid [MPA]) had lower median antibody titers compared with those who did not receive antimetabolites (continued)

injections were significantly correlated to each other (Figure 1a). Patients with a first kidney transplantation, a longer time from transplantation, better kidney function, and less immunosuppression were more likely to seroconvert (Table 1). Patients treated with calcineurin inhibitors, mycophenolate mofetil, or steroids showed significantly lower anti-SARS-CoV-2 antibody titers (Figure 1b–f). One patient developed a severe form of COVID-19 five days after the second injection.

In summary, the immunization rate among KTRs who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine can be as low as 48%. The issue of a third vaccine dose in nonresponsive KTRs is an intriguing one that could be usefully explored in further research.

1. Benotmane I, Gautier Vargas G, Cognard N, et al. Weak anti SARS CoV 2 antibody response after the first injection of an mRNA COVID 19 vaccine in kidney transplant recipients. *Kidney Int.* 2021;99:1487–1489.
2. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single dose of SARS CoV 2 messenger RNA vaccine in solid organ transplant recipients [e pub ahead of print]. *JAMA.* <https://doi.org/10.1001/jama.2021.4385>. Accessed April 22, 2021.
3. Centers for Disease Control and Prevention. Moderna COVID 19 vaccine overview and safety. Updated April 5, 2021. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html>. Accessed March 10, 2021.
4. Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS CoV 2 infection on humoral and T cell responses to single dose BNT162b2 vaccine. *Lancet.* 2021;397:1178–1181.

Ilies Benotmane^{1,2}, Gabriela Gautier-Vargas¹,
Noëlle Cognard¹, Jérôme Olagne¹,
Françoise Heibel¹, Laura Braun-Parvez¹,
Jonas Martzloff¹, Peggy Perrin¹, Bruno Moulin^{1,2},
Samira Fafi-Kremer^{2,3} and Sophie Caillard^{1,2}
¹Department of Nephrology and Transplantation, University Hospital, Strasbourg, France, ²Inserm UMR S1109, Labex Transplantex, Fédération de Médecine Translationnelle, Université de Strasbourg, Strasbourg, France; and ³Department of Virology, University Hospital, Strasbourg, France

Correspondence: Ilies Benotmane, Department of Nephrology and Transplantation, Strasbourg University Hospital, 1 Place de l'Hopital, 67091 Strasbourg, Cedex, France. E mail: ilies.benotmane@chru-strasbourg.fr

Kidney International (2021) 99, 1498–1500; <https://doi.org/10.1016/j.kint.2021.04.005>

Copyright © 2021, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Outcome of diacylglycerol kinase epsilon-mediated hemolytic uremic syndrome in an infant



To the editor: We read with great interest the article by Brocklebank *et al.* entitled “Long-Term Outcomes and Response to Treatment in Diacylglycerol Kinase Epsilon Nephropathy” in the June 2020 issue of *Kidney International*.¹ We also had a patient with diacylglycerol kinase epsilon (DGKE) nephropathy who presented with hemolytic uremic syndrome (HUS). He was admitted with decreased urine output for 2 days when he was 70 days old. He also had nonbloody diarrhea without fever. He had hemolytic anemia, thrombocytopenia, and kidney failure. Plasma complement C3 and a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 activity was normal. Eculizumab was given on the third day of admission. On the 10th day, he was discharged with normal kidney functions; eculizumab therapy was continued with 2-week intervals. Three months later, he presented with an HUS relapse after upper respiratory system infection under eculizumab therapy. Afterwards, genetic analysis results were obtained; a compound heterozygous mutation (i.e., p.Gln143* on exon 1 and p.Pro378Arg on exon 7) of DGKE was identified. Eculizumab was stopped at the age of 3 years. No relapse has been observed since then. Now he is 6 years old, with normal renal functions; he is receiving enalapril, 0.5 mg/kg per day, and losartan, 0.6 mg/kg per day, because of ongoing proteinuria, which was 160 mg/d (10.5 mg/m² per hour) at his last visit. In summary, he had a severe HUS relapse under eculizumab therapy, whereas he is without relapse during 3 years after stopping eculizumab. We agree with the fact that eculizumab is useless in DGKE-mediated atypical HUS and that it can be safely withdrawn in these individuals to avoid adverse effects, including severe infections.

1. Brocklebank V, Kumar G, Howie AJ, et al. Long term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. *Kidney Int.* 2020;97:1260–1274.

Figure 1 | (continued) (21.2 [interquartile range {IQR}, 6.8–401.9] AU/ml vs. 147.4 [IQR, 27.5–3352.5] AU/ml, respectively; $P = 0.0005$). (c) Kidney transplant recipients being treated with steroids had lower median antibody titers compared with those who did not receive steroids (17.9 [IQR, 6.8–378.9] AU/ml vs. 74.8 [IQR, 7.2–2417.9] AU/ml; $P = 0.002$). (d) Kidney transplant recipients being treated with calcineurin inhibitors (CNIs) had lower median antibody titers compared with those who did not receive CNIs (18.1 [IQR, 6.8–330] AU/ml for patients under tacrolimus and 76.6 [IQR, 10.1–2392.2] AU/ml for patients under cyclosporine vs. 220 [IQR, 6.8–4269] AU/ml for patients who did not receive CNIs). (e) Kidney transplant recipients being treated with tacrolimus + antimetabolites (MMF/MPA) had lower median antibody titers compared with those did not (9.2 [IQR, 6.8–110.2] AU/ml vs. 90.9 [IQR, 7.7–1976] AU/ml, respectively; $P < 0.0001$). (f) Kidney transplant recipients being treated with tacrolimus + antimetabolites (MMF/MPA) + steroids had lower median antibody titers compared with those who did not (6.8 [IQR, 6.8–57.4] AU/ml vs. 79.4 [IQR, 6.9–1393.5] AU/ml, respectively; $P < 0.0001$).